The Goldman Sachs Group Begins Coverage on Silence Therapeutics (NASDAQ:SLN)

Investment analysts at The Goldman Sachs Group assumed coverage on shares of Silence Therapeutics (NASDAQ:SLN) in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “sell” rating and a $6.00 price target on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 21.95% from the stock’s previous close.

A number of other equities research analysts also recently commented on the company. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Chardan Capital reiterated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Silence Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

Silence Therapeutics Price Performance

SLN opened at $4.92 on Tuesday. The company has a market capitalization of $147.26 million, a price-to-earnings ratio of -3.13 and a beta of 1.05. Silence Therapeutics has a 1-year low of $4.82 and a 1-year high of $27.72. The business has a 50 day moving average price of $6.33 and a two-hundred day moving average price of $13.08.

Institutional Trading of Silence Therapeutics

A number of hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in shares of Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after acquiring an additional 5,233 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Silence Therapeutics in the third quarter worth $56,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics in the fourth quarter worth $69,000. FNY Investment Advisers LLC acquired a new position in shares of Silence Therapeutics in the fourth quarter worth $120,000. Finally, Verition Fund Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter worth $207,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.